Management of Uterine Arteriovenous Malformation- a Comparison of 2 Management Possibilities- Observation vs. Progesterone Treatment/ a Randomized Control Trial

NCT05491343 Phase 4 UNKNOWN

A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation

Details

Lead sponsor	HaEmek Medical Center, Israel
Phase	Phase 4
Status	UNKNOWN
Enrolment	28
Start date	2022-08
Completion	2024-01

Conditions

• Arteriovenous Malformations

Interventions

• MedroxyPROGESTERone Injection [Depo-Provera]
• Other

Primary outcomes

• AVM regression — 3 weeks
  The time from diagnosis to regression